EQS-News

Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation 31.03.2026, 14:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Proxygen GmbH / Key word(s): Personnel
Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation

31.03.2026 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Vienna, Austria, March 31, 2026 - Proxygen, a biotechnology company pioneering the discovery of molecular glue degraders and next-generation proximity-based therapeutics, today announced the appointment of Chiara Conti, Ph.D., as Chief Scientific Officer (CSO). 

Dr. Conti joins Proxygen from Blueprint Medicines, where she identified four development candidates in seven years. Two of these were advanced to IND with unprecedented speed, while she also supported two additional clinical programs in Phase I. During her tenure, she established the company’s targeted protein degradation (TPD) platform and early-stage portfolio. Dr. Conti will lead Proxygen’s transition from discovery to clinical-stage execution, focusing on advancing the company’s pipeline into clinical development.  

“Over the past five years, we have built one of the most advanced discovery engines for molecular glue degraders, consistently delivering differentiated assets,” said Bernd Boidol, Ph.D., Chief Executive Officer of Proxygen. “Chiara’s appointment comes at a pivotal moment as we are now expanding into the broader induced proximity field, extending beyond degradation into a wider range of effectors. Her track record of rapidly translating discovery into IND-stage programs will be critical in accelerating our transition into the clinic. We are moving induced proximity from a discovery paradigm to a scalable, design-driven therapeutic modality.” 

“I have known Proxygen since its establishment and followed its innovation over the years. Proxygen’s platform stands out for the depth of its scientific foundation in proximity-driven protein degradation and its ability to systematically harness that knowledge to identify novel therapeutics,” said Dr. Conti. “The opportunity to extend this platform beyond degradation into a broader induced-proximity engine is incredibly compelling, offering significant potential while advancing the existing portfolio.” 

Proxygen will continue to invest in its degradation platform to maintain a dense and differentiated pipeline while expanding into new effector classes. This dual strategy reflects the company’s belief that induced proximity is a versatile therapeutic approach with the potential to address high-value targets beyond the current scope of drug discovery. 

The company has established multiple pharmaceutical partnerships, including with Merck & Co (known as MSD outside the U.S. and Canada), underscoring strong industry interest in proximity-based therapeutics. 

_DZN4805-1(c)KidizinSanetest

Chiara Conti, PhD, © Proxygen GmbH
 

About Proxygen

Proxygen is a Vienna-based biotechnology company developing a new class of therapeutics based on induced proximity. Building on deep expertise in molecular glue degraders, the company is expanding into a broader range of proximity-inducing mechanisms to reprogram cellular biology and address high-value targets across oncology and beyond. Proxygen combines computational design, chemical biology, and functional genomics to systematically discover and develop proximity-based therapeutics.
 

Contact

Bernd Boidol, Ph.D.
Chief Executive Officer
management@proxygen.com

For media inquiries

MC Services AG
Anne Hennecke/Lydia Robinson-García, Ph.D.

Phone: +49 (0)170 7134018
E-Mail: proxygen@mc-services.eu

 


31.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2300438  31.03.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer